Masatoshi Kudo

Jan 5, 2025 | nature.com | Masatoshi Kudo

AbstractThis study evaluated the long-term efficacy and safety of the widely used drugs entecavir (ETV) and tenofovir alafenamide (TAF), as well as the incidence of HCC.A nonrandomized, prospective, observational analysis included 77 patients with chronic hepatitis B who were assigned to continue ETV or switch TAF. After 240 weeks, the mean changes in serum hepatitis B surface antigen (− 0.365 ± 0.069 log IU/mL vs.

Oct 5, 2023 | jamanetwork.com | Shukui Qin |Masatoshi Kudo |Kindai Faculty |Tim Meyer

Key PointsQuestion  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically higher and more durable objective responses than sorafenib.

Sep 6, 2023 | futuremedicine.com | Ghassan Abou Alfa |George Lau |Masatoshi Kudo |Stephen Chan

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereFinancial & competing interests disclosureThis study was sponsored by AstraZeneca. We thank the participants in this study and their families, all the investigators and study site personnel, and the members of the independent data monitoring committee.

Jul 24, 2023 | pubmed.ncbi.nlm.nih.gov | Masatoshi Kudo

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software

Jun 8, 2023 | physiciansweekly.com | Rebecca Shover |Masatoshi Kudo

Adjuvant therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to results from the phase 3 IMbrave050 clinical trial (NCT04102098), which were presented by Masatoshi Kudo, MD, PhD, (Kindai University, Japan) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Physician’s Weekly interviews Dr. Kudo to learn more.